- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02354339
Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
The metabolic syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers from the disease and predispose the onset of diseases like cardiovascular disease and diabetes mellitus type 2.
The first line of treatment for metabolic syndrome is diet and exercise but patients have a low attachment to the treatment, so pharmacologic therapy is required. There is no a single drug that could help to the treatment of all metabolic syndrome components.
Irvingia gabonensis, better known as African mango, is widely consumed in central and western Africa, mainly the fruit and seeds. Besides being part of the diet of African the seeds have been used for the treatment of diseases such as dysentery, diabetes and as an analgesic.
Resent investigations have demonstrated that an extract of African mango seeds induce significantly weight loss in subjects with obesity, and also improves some biochemical parameters such as glucose and the lipid profile.
The aim of this study is to evaluate the effect of Irvingia gabonensis on metabolic syndrome, insulin secretion and insulin sensitivity.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A randomized, double-blind, placebo-controlled, clinical trial is going to be carried out in 24 patients of both sexes aged between 30 and 60 years, with diagnosis of metabolic syndrome according to the modified International Diabetes Federation (IDF) criteria (without diabetes and without previous treatment for metabolic syndrome components).
The patients will be assigned randomly into two groups of 12 patients each. The patients will receive 150 mg of Irvingia gabonensis before breakfast and dinner (300 mg per day) or placebo during 12 weeks.
Waist circumference, triglycerides, high density lipoproteins (HDL-c) and blood pressure will be evaluated before and after intervention in both groups.
First phase of insulin secretion (Stumvoll index), total insulin secretion (Insulinogenic index) and Insulin sensitivity (Matsuda index) will be calculated from the concentration of glucose and insulin obtained from an Oral Glucose Tolerance Test.
Data from statistical analysis will be presented through measures of central tendency and dispersion, mean and standard deviation for quantitative variables and frequencies and percentages for qualitative variables. Qualitative variables will be analyzed by X2. The inter group differences will be analyzed through Mann-Whitney U test and Wilcoxon Test for intra-group differences. Statistical significance will be considered with a p<0.05.
This protocol was approved by a local ethics committee and written informed consent will be obtained from all volunteers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- Instituto de Terapéutica Experimental y Clínica
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients both sexes
- Age between 30 and 60 years
- Metabolic syndrome according IDF modified criteria
- Waist circumference: Men ≥90 cm, women ≥80 cm
And two of the following criteria:
- HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL
- Fasting glucose ≥100 mg/dL
- Triglycerides ≥150 mg/dL
- Blood pressure ≥130/85 mmHg
- Informed consent signed
Exclusion Criteria:
- Women with confirmed or suspected pregnancy
- Women under lactation and/or puerperium
- Known hypersensibility to Irvingia gabonensis
- Physical impossibility for taking pills
- Known uncontrolled renal, hepatic, heart or thyroid disease
- Previous treatment for the metabolic syndrome components
- Body mass index ≥ 39.9 kg/m2
- Fasting glucose ≥126 mg/dL
- Triglycerides ≥ 500 mg/dL
- Total cholesterol ≥ 240 mg/dL
- LDL-C ≥190 mg/dL
- Blood pressure ≥140/90 mmHg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Irvingia gabonensis
Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
|
Intervention will be administered 30 minutes before meals
Other Names:
|
Placebo Comparator: Placebo
Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
|
Intervention will be administered 30 minutes before meals
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting Glucose Levels at Week 12
Time Frame: 12 weeks
|
Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques
|
12 weeks
|
Triglycerides Levels at Week 12
Time Frame: 12 weeks
|
Triglycerides will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques
|
12 weeks
|
High Density Lipoprotein (HDL-C) Levels at Week 12
Time Frame: 12 weeks
|
The HDL-C will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques
|
12 weeks
|
Systolic Blood Pressure at Week 12
Time Frame: 12 weeks
|
The systolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer
|
12 weeks
|
Diastolic Blood Pressure at Week 12.
Time Frame: Baseline. Week 12
|
The diastolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer
|
Baseline. Week 12
|
Waist Circumference at Week 12
Time Frame: 12 weeks
|
The waist circumference will be evaluated at baseline and at week 12 with a flexible validated metric tape
|
12 weeks
|
First Phase of Insulin Secretion at Week 12
Time Frame: 12 weeks
|
The first phase of insulin secretion will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test. Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis. First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion |
12 weeks
|
Total Insulin Secretion at Week 12
Time Frame: 12 weeks
|
Total insulin secretion will be calculated at baseline and week 12 with the insulinogenic index from concentrations of glucose and insulin obtained of an oral glucose tolerance test. The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus. Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion |
12 weeks
|
Total Insulin Sensitivity at Week 12
Time Frame: 12 weeks
|
Insulin sensitivity will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test. Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Weight at Week 12
Time Frame: 12 weeks
|
The body weight will be measured at baseline and week 12 with a bioimpedance balance.
|
12 weeks
|
Body Mass Index at Week 12
Time Frame: 12 weeks
|
The body mass index will be calculated at baseline and week 12 with the Quetelet index
|
12 weeks
|
Total Cholesterol at Week 12
Time Frame: 12 weeks
|
Total cholesterol will be estimated bye standardized techniques at baseline and week 12
|
12 weeks
|
Low Density Lipoproteins (LDL-C) at Week 12
Time Frame: 12 weeks
|
The LDL-C will be calculated at baseline and week 12 with the Friedewald formula
|
12 weeks
|
Aspartate Aminotransferase at Week 12
Time Frame: 12 weeks
|
The aspartate aminotransferase will be determinated by standardized techniques at baseline and week 12
|
12 weeks
|
Alanine Aminotransferase at Week 12
Time Frame: 12 weeks
|
The alanine aminotransferase will be determinated by standardized techniques at baseline and week 12
|
12 weeks
|
Creatinine at Week 12
Time Frame: 12 weeks
|
Creatinine levels will be measured at baseline and week 12 with standardized techniques
|
12 weeks
|
Uric Acid at Week 12
Time Frame: 12 weeks
|
Uric acid levels will be measured at baseline and week 12 with standardized techniques
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: MANUEL GONZALEZ, PhD, University of Guadalajara
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS-IGABONENSIS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome X
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Federal University of São PauloCompletedPhysical Activity | Endothelial Dysfunction | Metabolic Syndrome xBrazil
-
Midwest Biomedical Research FoundationSuspended
-
Instituto de Seguridad y Servicios Sociales de...Enrolling by invitationCardiovascular Diseases | Mediterranean Diet | Metabolic Syndrome xMexico
-
Wake Forest University Health SciencesBrigham and Women's HospitalCompletedDiabetes | Metabolic Syndrome xUnited States
-
University of PennsylvaniaAbbottCompletedMetabolic Syndrome xUnited States
-
Queen Margaret UniversityUnknownCardiovascular Diseases | Metabolic Syndrome XUnited Kingdom
-
Arne AstrupUniversity of Aarhus; University Hospital, Gentofte, Copenhagen; Technical University...CompletedMetabolic Syndrome XDenmark
Clinical Trials on Irvingia gabonensis
-
Gateway Health AllianceCompletedObesity | Overweight | Dyslipidemia